Pharmacogenetic determination of the effects of codeine and prediction of drug interactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1165-1174

  Caraco, Yoseph ^a,b   Sheller, James ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; DEBRISOQUINE; PLACEBO; QUINIDINE;

ADULT; ARTICLE; BIOTRANSFORMATION; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG DETERMINATION; DRUG EFFECT; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CODEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; PUPIL; QUINIDINE; REFLEX, PUPILLARY; RESPIRATION;

EID: 0030432381     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. AGON, P., BRAECKMAN, R., VAN, HAVER, D., DENUTTE, H., GOETHALS, P., DONCHE, H., VERMULLEN, F., DEMAN, J. AND KAUFMAN, J. M.:: Drug distribution in dog brain studied by positron emission tomography. Biopharmaceut. Drug. Dispos. 9: 567-577, 1988.
2. 3H]GBR-12935 BINDING TO CYTOCHROME P450 IN THE HUMAN BRAIN. J. NEUROCHEM. 62: 342-348, 1994.
3. 3H]codeine phosphate in man and in the dog. Arzneim.-Forsch. 28: 308-311, 1978.
4. BELLVILLE, J. W. AND SEED, J. C.: The effect of drugs on the respiratory response to carbon dioxide. Anesthesiology 21: 727-741, 1960.
5. BERTILSSON, L., LOU, Y. Q. AND DU, Y. L.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51: 388-397, 1992.
6. BRADLEY, C. M. AND NICHOLSON, A. N.: Effects of a μ-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man. Br. J. Clin. Pharmacol. 22: 507-512, 1986.
7. BREIMER, D. D.: Interindividual variation in drug disposition. Clinical implication and methods of investigation. Clin. Pharmacokinet. 8: 371-377, 1983.
8. CHARY, S., GOUGHNOUR, B. R., MOULIN, D. E., THORPE, W. R., HARSANYI, Z. AND DARKE, A. C.: The dose-response relationship of controlled-release codeine (codeine contin) in chronic cancer pain. J. Pain. Symp. Manage. 9: 363-371, 1994.
9. CHEN, Z. R., IRVINE, R. J., BOCHNER, F. AND SOMOGYI, A. A.: Morphine formation from codeine in rat brain: A possible mechanism of codeine analgesia. Life Sci. 46: 1067-2074, 1990.
10. CHEN, Z. R., IRVINE, R. J., SOMOGYI, A. A. AND BOCHNER, F.: Mu receptor binding of some commonly used opioids and their metabolites. Life. Sci. 48: 2165-2171, 1991.
11. DESMEULES, J., GASCON, M. P., DAYER, P. AND MAGISTRIS, M.: Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 41: 23-26, 1991.
12. EGGEN, A. E. AND ANDREW, M.: Use of codeine analgesics in a general population. A Norwegian study of moderately strong analgesics. Eur. J. Clin. Pharmacol. 46: 491-496, 1994.
13. EICHELBAUM, M., BERTILSSON, L., KUPFER, A., STEINER, E. AND MEESE, C.: Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquin. Br. J. Clin. Pharmacol. 25: 505-508, 1988.
14. EICHELBAUM, M. AND GROSS, A. S.: The genetic polymorphism of debrisoquine/ sparteine metabolism - Clinical aspects. Pharmacol. Ther. 46: 377-394, 1990.
15. FRASER, H. F., NASH, T. L., VANHORN, G. D. AND ISBELL, H.: Use of miotic effect in evaluating analgesic drugs in man. Arch. Int. Pharmacodyn. XCVIII: 443-451, 1954.
16. FUNCK-BRENTANO, C., KROEMER, H. K., LEE, J. T. AND RODEN, D. M.: Propafenone. N. Eng. J. Med. 322: 518-525, 1990.
17. FUNCK-BRENTANO, C., THOMAS, G., JACQZ-AIGRAIN, E., POIRIER, J. M., SIMON, T., BEREZIAT, G. AND JAILLON, P.: Polymorphism of dextromethorphan metabolism: Relationship between phenotype, genotype and response to the administration of encainide in humans. J. Pharmacol. Exp. Ther. 263: 780-786, 1992.
18. FUNCK-BRENTANO, C., TURGEON, J., WOOSLEY, R. L. AND RODEN, D. M.: Effect of low dose quinidine on encinide pharmacokinetics and pharmacodynamics: Influence of genetic polymorphism. J. Pharmacol. Exp. Ther. 249: 134-142, 1989.
19. GROSSMAN, S. A.: Undertreatment of cancer pain: Barriers and remedies. Suppl. Care. Can. 1: 74-78, 1993.
20. GUENGERICH, F. P.: Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity. Toxicol. Lett. 70: 133-138, 1994.
21. HORAI, Y., NAKANO, M., ISHIZAKI, T., ISHIKAWA, K., ZHOU, H. H., ZHOU, B. J., LIAO, C. L. AND ZHANG, L. M.: Metoprolol and mephenytoin oxidation polymorphism in far eastern Oriental subjects, Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207, 1989.
22. IDLE, J. R., MAHGOUB, A., LANCASTER, R. AND SMITH, R. L.: Hypotensive response to debrisoquine and hydroxylation phenotype. Life. Sci. 22: 979-983, 1978.
23. INABA, T., TYNDALE, R. E. AND MAHON, W. A. Quinidine: Potent inhibition of sparteine and debrisoquine oxidation in vivo. Br. J. Clin. Pharmacol. 22: 199-200, 1986.
24. JACOX, A., CARR, D. AND PAYNE, R.: New clinical Practice guidelines for the management of pain in patients with cancer pain. N. Eng. J. Med. 330: 651-655, 1994.
25. JUSTINS, D. M.: Chronic pain management. Br. J. Hosp. Med. 52: 12-16, 1994.
26. KRISHNA, D. R. AND KLOTZ, U.: Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26: 144-160, 1994.
27. LEE, J. T., KROEMER, H. K., SILBERSTEIN, D. J., FUNK-BRENTANO, C., LINEBERRY, M. D., WOOD, A. J. J., RODEN, D. M. AND WOOSLEY, R. L.: The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N. Eng. J. Med. 322: 1764-1768, 1990.
28. LENNARD, M. S., SILAS, J. H., FREESTONE, S., RAMSAY, L. E., TUCKER, G. T. AND WOODS, H. F.: Oxidation phenotype - A major determinant of metoprolol metabolism and response. N. Eng. J. Med. 307: 1558-1560, 1982.
29. LENNARD, M. S., TUCKER, G. T., WOODS, H. F., SILAS, J. H. AND IYUN, A. O.: Stereoselective metabolism of metoprolol in Caucasians and Nigerians - Relationship to debrisoquine oxidation phenotype. Br. J. Clin. Pharmacol. 27: 613-616, 1989.
30. MILLER, C. D., ASBURY, A. J. AND BROWN J. H.: Pupillary effects of alfentanyl and morphine. Br. J. Anaesthes. 65: 415-417, 1990.
31. MORIKE, K. E. AND RODEN, D. M.: Quinidine-enhanced β-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin. Pharmacol. Ther. 55: 28-34, 1994.
32. MORTIMER, O., PERSSON, K., LADONA, M. G., SPALDING, D., ZANGER, U. M., MEYER, U. A. AND RANE, A.: Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immune identified cytochrome P-450IID1. Clin. Pharmacol. Ther. 47: 27-35, 1990.
33. MURRAY, R. B., ADLER, M. W. AND KORCZYN, A. D.: The pupillary effects of opioids. Life. Sci. 33: 495-509, 1983.
34. NAKAMURA, K., GOTO, F., RAY, W. A., MCALLISTER, C. B., JACQZ, E., WILKINSON, G. R. AND BRANCH, R. A.: Interethnic difference in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38: 402-408, 1985.
35. NIELSEN, M. D., BROSEN, K. AND GRAM, L. F.: A dose effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br. J. Clin. Pharmacol. 29: 299-304, 1990.
36. OATES, N. S., SHAH, R. R., IDLE, J. R. AND SMITH, R. L.: Phenformin-induced lactic addosis associated with impaired debrisoquine hydroxylation. Lancet 1: 837-838, 1981.
37. OTTON, S. V., SCHADEL, M., CHEUNG, S. W., KAPLAN, H. L., BUSTO, U. E. AND SELLERS, E. M.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54: 463-472, 1993a.
38. OTTON, S. V., WU, D., JOFFE, R. T., CHEUNG, S. W. AND SELLERS, E. M.: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53: 401-409, 1993b.
39. PERT, C. B. AND SNYDER, S. H.: Opiate receptor: Demonstration in nervous tissue. Science (Wash. DC) 179: 1011-1014, 1973.
40. 2 sensitivity after epidural morphine and buprenorphine in volunteers. Anesth. Anal. 66: 847-851, 1987.
41. READ, D. J. C.: A clinical method for assessing the ventilatory response to carbon dioxide. Aust. Ann. Med. 1: 20-32, 1967.
42. SEED, J. C., WALLENSTEIN, S. L., HOUDE, R. W. AND BELLVILLE, J. W.: A comparison of the analgesic and respiratory effects of dihydrocodeine and morphine in man. Arch. Int. Pharmacodyn. CXVI: 293-339, 1958.
43. SHAH, R. R., OATES, N. S., IDLE, J. R., SMITH, R. L. AND LOCKHART J. D. F.: Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br. Med. J. 284: 295-299, 1982.
44. SINDRUP, S. H., ARENDT-NIELSEN, L., BROSEN, K., BJERRING, P., ANGELO, H. R., ERIKSEN, B. AND GRAM, L. F.: The effect of quinidine on the analgesic effect of codeine. Br. J. Clin. Pharmacol. 42: 587-592, 1992.
45. SINDRUP, S. H., BROSEN, K., BJERRING, P., ARENDT-NIELSEN, L., LARSEN, U., ANGELO, H. R. AND GRAM, L. F.: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. 49: 686-693, 1991.
46. SANFILIPPO, G.: Contributo sperimentale all' ipotesi della smetilazione della codeine nell' organismo. I. Inflenze della dose sull' assuefazione alla codeine. II. assuefazione alla codeine attenuta con somministrazione prolungata di morfina. Bull. Soc. Ital. Biol. Sper. 24: 723-726, 1948.
47. STONE, B. M.: Pencil and paper tests, sensitivity to psychotropic drugs. Br. J. Clin. Pharmacol. 18: 15S-20S, 1984.
48. TUCKER, G. T.: Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol. 46: (Suppl.) 417-424, 1994.
49. WECHSLER, D.: A Manual for the Wechsler Adult Intelligence Scale, Psychological Corporation, New York, 1981.
50. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.
51. YUE, Q. Y., HASSELSTRÖM, J. SVENSSON, J. O. AND SÄWE J.: Pharmacokinetics of codeine and its metabolites in Caucasians healthy volunteers: Comparison between extensive and poor hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 31: 635-642, 1991.
52. YUE, Q. Y., SVENSSON, J. O., ALM, C., SJÖQVIST, F. AND SÄWE, J.: Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 28: 639-645, 1989.
53. ZHOU, H. H., ANTHONY, L. B., RODEN, D. M. AND WOOD, A. J. J.: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin. Pharmacol. Ther. 47: 686-693, 1990.